Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pazopanib
Drug ID BADD_D01687
Description Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Indications and Usage Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
Marketing Status approved
ATC Code L01EX03
DrugBank ID DB06589
KEGG ID D05380
MeSH ID C516667
PubChem ID 10113978
TTD Drug ID Not Available
NDC Product Code Not Available
UNII 7RN5DR86CK
Synonyms pazopanib | GW 786034B | GW786034B | GW-786034B | GW 780604 | GW780604 | GW-780604 | Votrient
Chemical Information
Molecular Formula C21H23N7O2S
CAS Registry Number 444731-52-6
SMILES CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Skin hypopigmentation23.05.02.0030.002149%
Skin necrosis23.03.03.0110.000112%Not Available
Skin ulcer24.04.03.007; 23.07.03.0030.001701%
Sleep disorder19.02.04.001--Not Available
Small intestinal perforation07.04.06.0060.000168%
Somnolence19.02.05.003; 17.02.04.006--
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.003--Not Available
Spinal cord compression17.10.01.0060.000280%
Squamous cell carcinoma16.16.01.0020.000168%Not Available
Stomatitis07.05.06.0050.007913%
Sudden death08.04.01.003; 02.03.04.0130.000224%
Supraventricular extrasystoles02.03.03.0110.000112%Not Available
Supraventricular tachycardia02.03.03.0120.000168%
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Tenderness08.01.08.0050.000302%Not Available
Thrombocytopenia01.08.01.0020.002765%Not Available
Thrombosis24.01.01.006--Not Available
Thrombotic microangiopathy24.01.01.013; 20.01.07.004; 01.01.02.006--Not Available
Thrombotic thrombocytopenic purpura24.07.06.014; 23.06.01.011; 01.08.01.005--
Thyroid disorder05.02.01.0020.000806%Not Available
Thyroid function test abnormal13.10.06.001--Not Available
Thyroiditis05.02.04.0010.000112%Not Available
Tongue blistering07.14.02.0140.000246%Not Available
Tongue disorder07.14.01.0020.000246%Not Available
Tooth loss12.01.17.026; 07.09.09.0010.000381%Not Available
Toothache07.09.06.0010.000604%
Torsade de pointes02.03.04.005--Not Available
Transient ischaemic attack17.08.04.001; 24.04.06.005--
Tricuspid valve incompetence02.07.05.0010.000112%Not Available
Tumour lysis syndrome16.32.03.002; 14.05.01.0040.000616%
The 13th Page    First    Pre   13 14 15 16 17    Next   Last    Total 21 Pages